Biomedical Engineering Reference
In-Depth Information
4. Biotech set to dominate drug industry growth on World Wide
Web. 2009 Available at
http://www.evaluatepharma.com/
U niversal/View.aspx?t yp e
¼
Story&id
¼
188700 & se ctionID
¼
&i sEPVa n ta ge
¼
yes.
5. Huang, C. (2009). Receptor-Fc fusion therapeutics, traps, and
MIMETIBODY technology. Curr Opin Biotechnol 20(6),
692-699
6. Kastin AJ. (2006) Handbook of Biologically Active Peptides.
Academic Press, Amsterdam.
7. Adessi C, Soto C. (2002) Converting a peptide into a drug:
strategies to improve stability and bioavailability. Curr. Med.
Chem. 9, 963-978.
8. Gill TJ, 3rd, Gould HJ, Doty P. (1963) Role of optical isomers
in determining the antigenicity of synthetic polypeptides.
Nature 197, 746-747.
9. Tyndall JD, Nall T, Fairlie DP. (2005) Proteases universally
recognize beta strands in their active sites. Chem. Rev. 105,
973-999.
10. Li P, Roller PP. (2002) Cyclization strategies in peptide
derived drug design. Curr. Top. Med. Chem. 2, 325-341.
11. Blackwell HE, Sadowsky JD, Howard RJ, Sampson JN, Chao
JA, Steinmetz WE, et al. (2001) Ring-closing metathesis of
olefinic peptides: design, synthesis, and structural characteri-
zation of macrocyclic helical peptides. J. Org. Chem. 66,
5291-5302.
12. Verdine GL, Walensky LD. (2007) The challenge of drug-
ging undruggable targets in cancer: lessons learned from
targeting BCL-2 family members. Clin. Cancer Res. 13,
7264-7270.
13. Henchey LK, Jochim AL, Arora PS, Henchey LK, Jochim
AL, Arora PS. (2008) Contemporary strategies for the stabi-
lization of peptides in the alpha-helical conformation. Curr.
Opin. Chem. Biol. 12, 692-697.
14. Saladin PM, Zhang BD, Reichert JM, Saladin PM, Zhang BD,
Reichert JM. (2009) Current trends in the clinical develop-
ment of peptide therapeutics. Idrugs 12, 779-784.
15. Wilson AC, Meethal SV, Bowen RL, Atwood CS, Wilson
AC, Meethal SV, et al. (2007) Leuprolide acetate: a drug of
diverse clinical applications. Expert Opin. Investig. Drugs
16, 1851-1863.
16. Wingfield M, Healy DL. (1993) Endometriosis: medical
therapy. Baillieres Clin. Obstet. Gynaecol. 7, 813-838.
17. Lamberts SW, Reubi JC, Krenning EP. (1992) Somatostatin
analogs in the treatment of acromegaly. Endocrinol. Metab.
Clin. North Am. 21, 737-752.
18. Peeters M, Van den Brande J, Francque S. (2010) Diarrhea
and the rationale to use Sandostatin. Acta Gastroenterol.
Belg. 73, 25-36.
19. Blick SK, Dhillon S, Keam SJ, Blick SKA, Dhillon S, Keam
SJ. (2008) Teriparatide: a review of its use in osteoporosis.
Drugs 68, 2709-2737.
20. Overington JP, Al-Lazikani B, Hopkins AL. (2006) How
many drug targets are there? Nat. Rev. Drug Discov. 5, 4.
21. Cochran AG. (2000) Antagonists of protein-protein interac-
tions. Chem. Biol. 7, R85-R94.
22. Bailon P, Won CY, Bailon P, Won CY. (2009) PEG-modified
biopharmaceuticals. Expert Opin. Drug Deliv. 6, 1-16.
23. Roberts MJ, Bentley MD, Harris JM. (2002) Chemistry for
peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54,
459-476.
24. Werle M, Bernkop-Schnurch A. (2006) Strategies to improve
plasma half life time of peptide and protein drugs. Amino
Acids 30, 351-367.
25. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK,
Woodburn KW, et al. (2006) Evaluation of the safety and
pharmacodynamics of Hematide, a novel erythropoietic
agent, in a phase 1, double-blind, placebo-controlled,
dose-escalation study in healthy volunteers. Blood 108,
1830-1834.
26. McGregor DP. (2008) Discovering and improving
novel peptide therapeutics. Curr. Opin. Pharmacol. 8,
616-619.
27. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al.
(2005) Synthesis, characterization, and pharmacokinetic
studies of PEGylated glucagon-like peptide-1. Bioconjug.
Chem. 16, 377-382.
28. St Onge EL, Miller SA. (2010) Albiglutide: a new GLP-1
analog for the treatment of type 2 diabetes. Expert Opin. Biol.
Ther. 10, 801-806.
29. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-
TorresM, Flisiak R, et al. (2010) AlbinterferonAlfa-2bwas not
inferior to pegylated interferon- in a randomized trial of
patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology 139, 1267-1276.
30. Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D,
Gu ML, et al. (2002) Albugranin, a recombinant human
granulocyte colony stimulating factor (G-CSF) genetically
fused to recombinant human albumin induces prolonged
myelopoietic effects in mice and monkeys. Pharm. Res.
19, 1720-1729.
31. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral
OK, Chen C, et al. (2005) Development of a long-acting
insulin analog using albumin fusion technology. Diabetes 54,
251-258.
32. Wang W, Ou Y, Shi Y. (2004) AlbuBNP, a recombinant
B-type natriuretic peptide and human serum albumin fusion
hormone, as a long-term therapy of congestive heart failure.
Pharm. Res. 21, 2105-2111.
33. Abraham S, Guo F, Li LS, Rader C, Liu C, Barbas CF, 3rd,
et al. (2007) Synthesis of the next-generation therapeutic
antibodies that combine cell targeting and antibody-
catalyzed prodrug activation. Proc.Natl.Acad.Sci.USA
104, 5584-5589.
34. Lencer WI, Blumberg RS. (2005) A passionate kiss, then run:
exocytosis and recycling of IgG by FcRn. Trends Cell Biol.
15, 5-9.
35. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc
receptor comes of age. Nat. Rev. Immunol. 7, 715-725.
36. Goldenberg MM. (1999) Etanercept, a novel drug for the
treatment of patients with severe, active rheumatoid arthritis.
Clin. Ther. 21, 75-87; discussion 71-72.
Search WWH ::
Custom Search